Innoviva shareholders reelect board, approve compensation and equity plan

At the Meeting, our stockholders also approved Innoviva’s 2026 Equity Incentive Plan. The vote for such approval was 55,435,111 shares for, 3,766,788 shares against, 36,028 shares abstaining, and 6,809,010 shares of broker non-votes.

Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 66,008,453 shares for, 16,574 shares against, 21,910 shares abstaining and 0 broker non-votes.

At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 56,243,880 shares for, 2,836,001 shares against, 158,046 shares abstaining, and 6,809,010 shares of broker non-votes.

At the Annual Meeting of Stockholders held on May 4, 2026 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non-Votes Derek Small 56,752,327 2,485,600 6,809,010 Mark A. DiPaolo, Esq. 50,072,119 9,165,808 6,809,010 Jules Haimovitz 56,834,625 2,403,302 6,809,010 Sarah J. Schlesinger, M.D. 53,509,479 5,728,448 6,809,010 Pavel Raifeld 58,880,013 357,914 6,809,010